// COMPANY
Nouscom
SECTOR BIOTECHMENTIONS 1LAST SEEN OCTOBER 19, 2026
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
funding·Axios Pro Rata·OCTOBER 19, 2026
“Nouscom, a Swiss developer of immunotherapies, raised €120m in Series D funding from M Ventures, Revelation Partners, Angelini Industries, European Investment Bank...”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.